Dupilumab (Dupixent) will be added to the PBS from Thursday, April 1 for adolescents from age 12 years and adults with uncontrolled severe type 2 asthma. The PBS listing of the monoclonal antibody, which targets both IL-4 and IL-13, will benefit an estimated 1,700 people with allergic or eosinophilic asthma. Commenting on the new indication, ...
Dupilumab listed on the PBS for severe asthma
By Mardi Chapman
31 Mar 2021